摘要
目的:观察温阳复脉方对糖尿病下肢血管病变(lowerextremityatheroscleroticdisease,LEAD)的临床疗效。方法:选择57例LEAD患者,按排列表法随机分为2组,治疗组29例,对照组28例,对照组在基础治疗的基础上予以口服拜阿司匹灵100mg,每日1次,睡前口服。治疗组在对照组的基础上加用温阳复脉方口服。2组均以2周为1个疗程,治疗2个月。结果:2组有效率比较,差异具有统计学意义(P<0.05)。治疗后2组ABI值、血浆黏度、纤维蛋白原、CRP、尿微量白蛋白均较治疗前显著改善(P<0.01),且治疗组ABI值、血浆黏度、CRP、尿微量白蛋白显著高于对照组(P<0.05)。结论:温阳复脉方联合拜阿司匹灵治疗LEAD可提高临床疗效,降低血液黏稠度。
Objective： To observe the clinical effect of Wenyang Fumai Prescription on lower extremity atheroscle- rotic disease （ LEAD ） .Methods Fifty-seven patients with LEAD were randomly divided into two groups： treatment group （ n=29 ）, control group （ n=28 ）, the control group treatment on the basis of given Bayaspirin 100mg, 1 times daily, orally at bedtime.The treatment group in the control group on the basis of the addition of Wenyang Fumai Pre- scription oral, 2 weeks for 1 course of treatment, both groups were treated for 2 months.Results The total effective rate of the treatment group and the control group were 93. 1% and 64.3% respectively, the total effective rate of the two groups, the difference was statistically significant （ P〈0.05 ）. After treatment, ABI, Plasma viscosity, Fibrinogen, CRP and Urinary albumin were significantly improved （ P 〈0.01 ）, and ABI, Plasma viscosity, CRP and Urinary al- bumin were significantly higher in the treatment group than in Control group （ P 〈0.05 ）.Conclusion Wenyang Fumai Prescriotion combined with Bavasoirin treatment of LEAD can imorove clinical efficacy and reduce blood viscosity.
出处
《中医药临床杂志》
2017年第8期1324-1326,共3页
Clinical Journal of Traditional Chinese Medicine
作者简介
孟庆贺（1973-），男，副主任医师。研究方向：中西医结合治疗糖尿病及糖尿病并发症。E-mail：748922359@qq.com 唐祖宣（1942-），男，第二届国医大师，河南邓州中医院院长。 李廷振（1985-），男，主治医师，硕士研究生，亳州市华佗中医院内分泌科。
